Software developer for cell and gene therapy supply chain tracking and orchestration, TrakCel, has made a strategic appointment to further support its growth in the US. This comes after the recent opening of the company’s second US office in New Jersey.
UK-USA growth
The Cardiff-based company has appointed Dr Joe Vitale, from New Jersey, as the director of process engineering. “Over the last five years, TrakCel has made significant strides in becoming the leading provider of needle-to-needle cell orchestration technology to aid the delivery of regenerative therapies,” Vitale added. “Its technology has helped industry leaders improve efficiency and reliability of their products.”
With the various strategic appointments and its expanded US presence, TrakCel is aiming to triple its client base and revenue by the end of the year and increase its number of employees in the UK and the US to over 100 by the end of 2019. “The company is rapidly growing as the industry is increasingly recognizing the need to track and control therapies across multiple stakeholders, so I’m joining at a pivotal time in this corporate journey,” Vitale said.
“Joe has a vast amount of experience and understanding from the front-line of the cell and gene therapy industry; knowledge that will be extremely beneficial when we are liaising with clients from these industries,” explained Ravi Nalliah, chief executive officer at TrakCel. “Growing our presence in the US is a key target for us and Joe’s knowledge and contacts will be instrumental in helping us achieve this transatlantic growth.”